PROYECTOS CONVOCATORIA PÚBLICA

Projekt PI16/00002

HVEM / BTLA / CD160 Y PD-L1/PD1 como dianas inmunoterapéuticas en el tratamiento de tumores hematopoyéticos

Finanzier: INSTITUTO DE SALUD CARLOS III (ISCIII)

Dauer von 02 von April von 2019 bis 30 von September von 2020 (18 Monate) Fertig

23.740,70 EUR

Geltungsbereich National.

Bekanntmachung: (INSTITUTO DE SALUD CARLOS III (ISCIII))

Forscher/innen

Foto de Mª LUISA DEL

Verantwortlich

Foto de JOSE IGNACIO

RODRÍGUEZ BARBOSA

Publikationen im Zusammenhang mit dem Projekt (5)

Nach Typologie anzeigen

2024

Assesment of Hypoderma infestation in a wild population of Cervus elaphus from mountains Atlantic ecosystems in southwestern Europe (Spain)
Veterinary Research Communications

2023

Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression
Frontiers in Immunology

2022

The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection
Translational Research
Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
Frontiers in Immunology

2020

Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model
Cancer Immunology, Immunotherapy